Key result
Corticosteroids, plasma exchange, IVIG, and chemotherapeutics reduce inflammatory damage in acute transverse myelitis.
This article reviews the therapeutic approach to acute transverse myelitis and its early complications.
May inform acute transverse myelitis management; leaves open optimal regimens pending randomized trials.
Acute transverse myelitis (ATM) has many potential etiologies, but a significant proportion of cases are categorized as idiopathic despite thorough evaluation. Clinical presentation of ATM typically includes some combination of motor weakness, sensory symptoms, and bowel and bladder dysfunction. Prompt recognition, even before a final etiologic diagnosis is reached, is critical to initiating early therapeutic intervention to reduce the harmful effects of inflammation. Acute therapeutic options for ATM include corticosteroids, plasma exchange, IV immunoglobulin, and chemotherapeutic agents such as cyclophosphamide. In some instances, combinations of these therapies are used. This article examines the therapeutic approach to ATM and its various acute clinical manifestations.
No takes yet. Share an insight, caveat, or question.
Benjamin Greenberg (2011) conducted a review in Acute Transverse Myelitis. Acute therapeutic options (corticosteroids, plasma exchange, IV immunoglobulin, chemotherapeutic agents) was evaluated. Acute therapeutic options for acute transverse myelitis include corticosteroids, plasma exchange, IV immunoglobulin, and chemotherapeutic agents to reduce the harmful effects of inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: